Sino Biological, Inc. provides recombinant protein and antibody reagents for life science researchers in China and internationally. Its offerings include recombinant proteins, antibodies, cDNA clones, kits, serum-free media, protein modification products, qPCR primers, cell lysates, and purification reagents. The company also offers solutions for areas such as autoimmune disease research, kinase drug discovery, cytokine and growth factor research, SARS-CoV-2 variant research, CAR-T therapy, 3D organoids, ADC development, influenza vaccine development, multispecific antibody development, MSC therapy, and in vitro efficacy evaluation. It serves academic research institutions, biotech companies, and pharmaceutical companies, and was founded in 2016 with headquarters in Beijing, China.